Provenance
Written by SPS and the College of Sexual and Reproductive Healthcare (CoSRH), with the support of specialist stakeholders working within clinical practice, for use within reproductive services.
Under Review – June 2026
The CoSRH Statement: Meningioma and Progestogens published on the 4th June 2026 will require all the contraception PGD templates to be reviewed to ensure this new advice is reflected.
The Short Life Working Group will complete this review with the aim that any templates requiring an update will be republished by the end of July 2026.
If any organisation wishes to reflect the guidance within the local templates before this review has taken place they may do so in line with local policies.
PGD template attachment
The template PGD is attached below to download and use in conjunction with our implementation advice.
More reproductive health PGD templates
- Progestogen-Only Intra-Uterine Device (LNG-IUD) for contraception
- Etonogestrel (e.g. Nexplanon®) implant for contraception
- Combined hormonal contraceptive transdermal patch
- Combined hormonal contraceptive vaginal ring
- Ulipristal acetate 30mg tablets for emergency contraception
- Progestogen only pill (POP) for contraception
- Levonorgestrel 1500 microgram tablets for emergency contraception
- Combined oral hormonal contraceptive (COC) in reproductive health
- Medroxyprogesterone acetate (DMPA) IM injection for contraception
- Lidocaine injection for subdermal etonogestrel in contraception
- Lidocaine plus prilocaine cream for IUD insertion or removal
- Lidocaine 10mg/ml spray for IUD insertion or removal
- Copper Intrauterine Device (Cu-IUD)
All PGD templates
National PGD, protocol and written instructions templates
Update history
- Information added regarding CoSRH statement on Meningioma and Progestogens
- Republished
- Expired PGD template removed
- Revised template to reflect minor clarifications following feedback.
- Version 3.0 published
- Planned review detail added
- Information added regarding name change of FSRH to CoSRH
- Version 2.3 PGD template added. Updated contraindications and cautions in line with SmPC changes.
- Updated PGD template published - statement added regarding a suggested link between the prolonged use of medroxyprogesterone acetate and a small increased risk of intracranial meningioma in line with FSRH statement. Added exclusion of meningioma as per SPC.
- Version 2.1 published - minor changes to align with updated FSRH guidance
- Title, URL and summary amended.
- Expiring template removed.
- Version 2.0 PGD template added
- Published